Cell Lines: Immortalized Human Somatic Cells; Primary cells; Adult Stem Cells and IPS Cells; Cell Panels
Cell Culture Media: Ready-to-use Media; Basal Media & Supplements
Cell Derived Products: Genomic DNA; RNA; microRNA; Proteins
Cells and Services for in Vitro Test Systems
Cell lines will lead to replacement, reduction, and refinement (‘3R’s) of animal trials as well as of cells that do not reflect the tissue specific physiology of a cell based assay in question. Our cells are typically used in basic research, in pharmaceutical industry (drug and target identification, drug development, toxicology, bioactivity assays, lot release, quality control, efficacy testing), in chemical and cosmetic industries (toxicity testing, AOP, MoA testing) as well as in ecotoxicology.
RPTEC/TERT 1 HUVEC/TERT 2 LHCN-M2 HBEC3-KT HCEC-1CT
Cells and Services for Production
Today, more than 60% of recombinant proteins used for therapeutic applications are produced in mammalian cells. Although mammalian production systems are still costly and time consuming, when compared to bacterial or yeast expression systems, they offer unique advantages such as appropriate protein folding, assembly and posttranslational modification, factors that are major determinants for the biological activity and product quality. Nevertheless, it is of note that most commonly used mammalian expression systems have e.g. abnormal glycosylation patterns and thus may produce protein isoforms that differ from those synthesized in normal cells. Furthermore, differences in the glycosylation patterns produced by cells from different tissues accentuate the need for selection and establishment of novel host cell lines.
Cells and Services for Cell Based Therapies
Reprogramming of normal somatic cells into pluripotent stem cells based on key findings by Yamanaka has emerged as one of the most exciting promises of biomedical research over the past years. Reprogrammed cells are not only used as model system, but have already gained importance for novel cell based therapy.
Advanced the use of iPSCs due to a fully non-invasive protocol for generation of urine-derived cells for reprogramming. These cells can be isolated without ethical concern from any consenting individual, making them ideal for therapeutic applications as well as research purposes.
Developed protocols for the isolation and expansion of cells from fresh urine as well as frozen urine sediments, which can be reprogrammed using retroviral vectors as well as integration free methods including mRNA transfection. The reprogrammed cells show the typical markers of pluripotent stem cells.
Offer the establishment of iPS cell lines from specific donors concomitant with the analysis of typical markers of pluripotent stem cells as well as the establishment of differentiation protocols towards several lineages.